drugset / Trial / NCT06353997
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
Timeline
- Start
- 2024-09-05
- Primary completion
- 2027-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INBRX-106 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |